SG11201805253SA - Compositions and methods related to multimodal therapeutic cell systems for cancer indications - Google Patents

Compositions and methods related to multimodal therapeutic cell systems for cancer indications

Info

Publication number
SG11201805253SA
SG11201805253SA SG11201805253SA SG11201805253SA SG11201805253SA SG 11201805253S A SG11201805253S A SG 11201805253SA SG 11201805253S A SG11201805253S A SG 11201805253SA SG 11201805253S A SG11201805253S A SG 11201805253SA SG 11201805253S A SG11201805253S A SG 11201805253SA
Authority
SG
Singapore
Prior art keywords
massachusetts
international
cambridge
rule
methods related
Prior art date
Application number
SG11201805253SA
Inventor
Avak Kahvejian
Jordi Mata-Fink
Robert Deans
Tiffany Chen
John Round
Noubar Afeyan
Nissen Torben Straight
Nathan Dowden
Tom Wickham
Sivan Elloul
Original Assignee
Rubius Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rubius Therapeutics Inc filed Critical Rubius Therapeutics Inc
Publication of SG11201805253SA publication Critical patent/SG11201805253SA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/18—Erythrocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464402—Receptors, cell surface antigens or cell surface determinants
    • A61K39/464424—CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0641—Erythrocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 20 July 2017 (20.07.2017) WIPOIPCT (10) International Publication Number WO 2017/123646 A1 (51) International Patent Classification: A61K35/12 (2015.01) CI2N 5/10 (2006.01) A61K35/18 (2015.01) (21) International Application Number: (22) International Filing Date: (25) Filing Language: (26) Publication Language: PCT/US2017/013035 11 January 2017 (11.01.2017) English (30) Priority Data: 62/277,130 11 January 2016 (11.01.2016) 62/359,448 7 July 2016 (07.07.2016) 62/370,915 4 August 2016 (04.08.2016) 62/420,973 11 November 2016 (11.11.2016) English US US us us (71) Applicant: RUBIUS THERAPEUTICS, INC. [US/US]; 620 Memorial Dr #100W, Cambridge, Massachusetts 02139 (US). (72) Inventors: KAHVEJIAN, Avak; 1 Memorial Drive, 7th Floor, Cambridge, Massachusetts 02142 (US). MATA- FINK, Jordi; 8 Windsor Rd #1, Somerville, Massachusetts 02144 (US). DEANS, Robert, J.; 1609 Ramsgate Court, Riverside, California 92506 (US). CHEN, Tiffany, F.; 91 Sidney St. Apt 207, Cambridge, Massachusetts 02139 (US). ROUND, John; 1 Memorial Drive, 7th Floor, Cam­ bridge, Massachusetts 02142 (US). AFEYAN, Noubar, B.; 1 Sunset Ridge, Lexington, Massachusetts 02421 (US). STRAIGHT NISSEN, Torben; 68 Waban Hill Rd., Chestnut Hill, Massachusetts 02467 (US). DOWDEN, Nathan; 4 Goddu Ave., Winchester, Massachusetts 01890 (US). WICKHAM, Tom; 20 Hickory Lane, Groton, Mas­ sachusetts 1450 (US). ELLOUL, Sivan; 114 Eastbourne Rd., Newton, Massachusetts 02459 (US). (74) Agent: KOYFMAN, Hannah, R.; Lando & Anastasi, LLP, Riverfront Office Park, One Main Street, Suite 1100, Cambridge, Massachusetts 02142 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available)'. AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available)'. ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: — as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(H)) — as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) Published: — with international search report (Art. 21(3)) — with sequence listing part of description (Rule 5.2(a)) V© •t m CJ o CJ (54) Title: COMPOSITIONS AND METHODS RELATED TO MULTIMODAL THERAPEUTIC CELL SYSTEMS FOR CAN­ CER INDICATIONS (57) : The invention includes compositions and methods related to multimodal therapies, e.g., for treating a cancer. A mul­ timodal therapy described herein provides and/or administers a plurality of agents that function in a coordinated manner to provide a therapeutic benefit to a subject in need thereof, e.g., a subject having a cancer.
SG11201805253SA 2016-01-11 2017-01-11 Compositions and methods related to multimodal therapeutic cell systems for cancer indications SG11201805253SA (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662277130P 2016-01-11 2016-01-11
US201662359448P 2016-07-07 2016-07-07
US201662370915P 2016-08-04 2016-08-04
US201662420973P 2016-11-11 2016-11-11
PCT/US2017/013035 WO2017123646A1 (en) 2016-01-11 2017-01-11 Compositions and methods related to multimodal therapeutic cell systems for cancer indications

Publications (1)

Publication Number Publication Date
SG11201805253SA true SG11201805253SA (en) 2018-07-30

Family

ID=57907000

Family Applications (4)

Application Number Title Priority Date Filing Date
SG10201913837TA SG10201913837TA (en) 2016-01-11 2017-01-11 Compositions and methods related to multimodal therapeutic cell systems for cancer indications
SG11201805442XA SG11201805442XA (en) 2016-01-11 2017-01-11 Compositions and methods related to multimodal therapeutic cell systems for immune indications
SG10202007639SA SG10202007639SA (en) 2016-01-11 2017-01-11 Compositions and methods related to multimodal therapeutic cell systems for immune indications
SG11201805253SA SG11201805253SA (en) 2016-01-11 2017-01-11 Compositions and methods related to multimodal therapeutic cell systems for cancer indications

Family Applications Before (3)

Application Number Title Priority Date Filing Date
SG10201913837TA SG10201913837TA (en) 2016-01-11 2017-01-11 Compositions and methods related to multimodal therapeutic cell systems for cancer indications
SG11201805442XA SG11201805442XA (en) 2016-01-11 2017-01-11 Compositions and methods related to multimodal therapeutic cell systems for immune indications
SG10202007639SA SG10202007639SA (en) 2016-01-11 2017-01-11 Compositions and methods related to multimodal therapeutic cell systems for immune indications

Country Status (22)

Country Link
US (8) US10456421B2 (en)
EP (3) EP3402491B1 (en)
JP (5) JP2019501655A (en)
KR (2) KR20180095098A (en)
CN (3) CN115969987A (en)
AU (2) AU2017207738A1 (en)
BR (2) BR112018013853A2 (en)
CA (2) CA3010510A1 (en)
DK (1) DK3402491T3 (en)
ES (1) ES2907695T3 (en)
HK (1) HK1259079A1 (en)
HR (1) HRP20220147T1 (en)
HU (1) HUE057660T2 (en)
IL (2) IL260010A (en)
LT (1) LT3402491T (en)
MX (2) MX2018008515A (en)
PL (1) PL3402491T3 (en)
PT (1) PT3402491T (en)
RS (1) RS62939B1 (en)
SG (4) SG10201913837TA (en)
SI (1) SI3402491T1 (en)
WO (2) WO2017123644A1 (en)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE047507T2 (en) 2011-10-17 2020-04-28 Massachusetts Inst Technology Intracellular delivery
AU2014306423B2 (en) 2013-08-16 2019-04-18 Massachusetts Institute Of Technology Selective delivery of material to cells
JP6702866B2 (en) 2013-11-18 2020-06-03 ルビウス セラピューティクス， インコーポレイテッド Synthetic membrane-receiver complex
PL3125927T3 (en) 2014-04-01 2021-07-19 Rubius Therapeutics, Inc. Methods and compositions for immunomodulation
JP2017533702A (en) 2014-10-31 2017-11-16 マサチューセッツ インスティテュート オブ テクノロジー Delivery of biomolecules to immune cells
EP3218492A4 (en) 2014-11-14 2018-10-10 Massachusetts Institute Of Technology Disruption and field enabled delivery of compounds and compositions into cells
CA2971626A1 (en) 2015-01-12 2016-07-21 Massachusetts Institute Of Technology Gene editing through microfluidic delivery
CN107922911A (en) 2015-07-09 2018-04-17 麻省理工学院 Material is delivered to cytode
EP3344575B1 (en) 2015-09-04 2020-04-15 SQZ Biotechnologies Company Intracellular delivery of biomolecules to cells comprising a cell wall
ES2907695T3 (en) 2016-01-11 2022-04-26 Rubius Therapeutics Inc Compositions and methods related to multimodal therapeutic cellular systems for cancer indications
KR20190117667A (en) * 2017-02-17 2019-10-16 루비우스 테라퓨틱스, 아이엔씨. Functionalized red blood cells
US20210228738A1 (en) * 2017-07-17 2021-07-29 INSERM (Institut National de la Santé et de la Recherche Médicale) Compositions and methods for increasing or enhancing transduction of gene therapy vectors and for removing or reducing immunoglobulins
US10960071B2 (en) 2017-08-07 2021-03-30 The Regents Of The University Of California Platform for generating safe cell therapeutics
CA3072329A1 (en) 2017-08-07 2019-02-14 The Regents Of The University Of California Platform for generating safe cell therapeutics
JP2021500855A (en) * 2017-09-07 2021-01-14 キュー バイオファーマ， インコーポレイテッド Antigen-presenting polypeptides and how to use them
WO2019113512A1 (en) * 2017-12-07 2019-06-13 Flagship Pioneering Innovations V, Inc. Cytobiologics and therapeutic uses thereof
KR20200104887A (en) * 2017-12-23 2020-09-04 루비우스 테라퓨틱스, 아이엔씨. Artificial antigen presenting cells and methods of use
EP3762422A1 (en) * 2018-03-08 2021-01-13 Rubius Therapeutics, Inc. Therapeutic cell systems and methods for treating cancer and infectious diseases
US20210208163A1 (en) * 2018-05-24 2021-07-08 Rush University Medical Center ICOSL for use as a Renal Therapeutic
US11166996B2 (en) 2018-12-12 2021-11-09 Flagship Pioneering Innovations V, Inc. Anellovirus compositions and methods of use
CN113795580A (en) 2019-01-18 2021-12-14 旗舰创业股份有限公司 TREM compositions and uses thereof
MX2021010089A (en) * 2019-02-20 2021-12-10 Rubius Therapeutics Inc Engineered erythroid cells including loadable antigen-presenting polypeptides and methods of use.
JP2022523794A (en) 2019-03-04 2022-04-26 フラッグシップ パイオニアリング イノベーションズ シックス，エルエルシー Cyclic polyribonucleotide and pharmaceutical composition thereof
US20200299369A1 (en) * 2019-03-18 2020-09-24 Bio-Rad Abd Serotec Gmbh Antigen binding fragments conjugated to a plurality of fc isotypes and subclasses
KR20210142678A (en) 2019-03-25 2021-11-25 플래그쉽 파이어니어링 이노베이션스 브이아이, 엘엘씨 Compositions comprising modified circular polyribonucleotides and uses thereof
EP3963092A1 (en) * 2019-05-02 2022-03-09 Predictive Technology Group, Inc. Somatic cancer driver mutations in endometriosis lesions contribute to secondary cancer risk
WO2020243560A1 (en) 2019-05-31 2020-12-03 Flagship Pioneering, Inc. Uses of trem compositions to modulate trna pools
WO2020252436A1 (en) 2019-06-14 2020-12-17 Flagship Pioneering Innovations Vi, Llc Circular rnas for cellular therapy
EP3986469A1 (en) 2019-06-19 2022-04-27 Flagship Pioneering Innovations VI, LLC Compositions comprising circular polyribonucleotides for protein modulation and uses thereof
CN112195154B (en) * 2019-07-08 2024-03-29 江苏汇智生物科技有限公司 Cell for genetically modifying and expressing modified PLA2R receptor and application thereof
EP4025048A2 (en) 2019-09-05 2022-07-13 Hemanext Inc. Methods for the preservation of reagent red blood cells using carbon monoxide
WO2021073613A1 (en) * 2019-10-18 2021-04-22 Westlake Therapeutics (Hangzhou) Co. Limited Engineered red blood cells presenting specific cancer neoantigen with artificial mhc
WO2021092073A1 (en) 2019-11-04 2021-05-14 Flagship Pioneering, Inc. Methods of modifying a nucleic acid sequence
CN115003810A (en) 2019-11-04 2022-09-02 旗舰创业股份有限公司 TREM compositions for CON-rare codons and related uses
EP4096681A1 (en) 2020-01-29 2022-12-07 Flagship Pioneering Innovations VI, LLC Delivery of compositions comprising circular polyribonucleotides
EP4096715A1 (en) 2020-01-29 2022-12-07 Flagship Pioneering Innovations VI, LLC Compositions comprising linear polyribonucleotides for protein modulation and uses thereof
US20230181620A1 (en) 2020-01-29 2023-06-15 Flagship Pioneering Innovations Vi, Llc Compositions for translation and methods of use thereof
KR20220140542A (en) * 2020-02-07 2022-10-18 더 리전트 오브 더 유니버시티 오브 캘리포니아 Methods and uses for bioengineered preparation of enucleated cells
CN116322760A (en) 2020-05-20 2023-06-23 旗舰创业创新第六有限责任公司 Coronavirus antigen composition and use thereof
EP4153152A1 (en) 2020-05-20 2023-03-29 Flagship Pioneering Innovations VI, LLC Compositions and methods for producing human polyclonal antibodies
CA3179444A1 (en) 2020-05-20 2021-11-25 Avak Kahvejian Immunogenic compositions and uses thereof
US20230203509A1 (en) 2020-05-29 2023-06-29 Flagship Pioneering Innovations Vi, Llc Trem compositions and methods relating thereto
US20230203510A1 (en) 2020-05-29 2023-06-29 Flagship Pioneering Innovations Vi, Llc Trem compositions and methods relating thereto
EP4167984A1 (en) 2020-06-23 2023-04-26 Flagship Pioneering, Inc. Anti-viral compounds and methods of using same
AU2021336976A1 (en) 2020-09-03 2023-03-23 Flagship Pioneering Innovations Vi, Llc Immunogenic compositions and uses thereof
JP2024501288A (en) 2020-12-23 2024-01-11 フラッグシップ パイオニアリング イノベーションズ シックス，エルエルシー Compositions of modified TREM and uses thereof
WO2022150569A1 (en) 2021-01-08 2022-07-14 Rubius Therapeutics, Inc. METHODS OF INCREASING NKp30-POSITIVE LYMPHOCYTES IN A SUBJECT AND USES THEREOF
EP4297784A1 (en) * 2021-02-26 2024-01-03 Cytonus Therapeutics, Inc. Compositions and methods for therapeutic delivery
TW202304482A (en) 2021-03-14 2023-02-01 美商盧比亞斯治療公司 Methods of increasing nkg2d-positive lymphocytes in a subject and uses thereof
US20220325287A1 (en) 2021-03-31 2022-10-13 Flagship Pioneering Innovations V, Inc. Thanotransmission polypeptides and their use in treating cancer
WO2023009547A1 (en) 2021-07-26 2023-02-02 Flagship Pioneering Innovations Vi, Llc Trem compositions and uses thereof
EP4271818A1 (en) 2021-09-17 2023-11-08 Flagship Pioneering Innovations VI, LLC Compositions and methods for producing circular polyribonucleotides
WO2023064383A1 (en) * 2021-10-12 2023-04-20 Cytonus Therapeutics, Inc. Systems and methods for manufacturing of therapeutic cells
TW202322826A (en) 2021-10-18 2023-06-16 美商旗艦先鋒創新有限責任公司 Compositions and methods for purifying polyribonucleotides
WO2023096963A1 (en) 2021-11-24 2023-06-01 Flagship Pioneering Innovations Vi, Llc Varicella-zoster virus immunogen compositions and their uses
WO2023096990A1 (en) 2021-11-24 2023-06-01 Flagship Pioneering Innovation Vi, Llc Coronavirus immunogen compositions and their uses
WO2023097003A2 (en) 2021-11-24 2023-06-01 Flagship Pioneering Innovations Vi, Llc Immunogenic compositions and their uses
WO2023122745A1 (en) 2021-12-22 2023-06-29 Flagship Pioneering Innovations Vi, Llc Compositions and methods for purifying polyribonucleotides
WO2023122789A1 (en) 2021-12-23 2023-06-29 Flagship Pioneering Innovations Vi, Llc Circular polyribonucleotides encoding antifusogenic polypeptides
WO2023220083A1 (en) 2022-05-09 2023-11-16 Flagship Pioneering Innovations Vi, Llc Trem compositions and methods of use for treating proliferative disorders
WO2023220729A2 (en) 2022-05-13 2023-11-16 Flagship Pioneering Innovations Vii, Llc Double stranded dna compositions and related methods
WO2023230573A2 (en) 2022-05-25 2023-11-30 Flagship Pioneering Innovations Vii, Llc Compositions and methods for modulation of immune responses
WO2023230570A2 (en) 2022-05-25 2023-11-30 Flagship Pioneering Innovations Vii, Llc Compositions and methods for modulating genetic drivers
WO2023230549A2 (en) 2022-05-25 2023-11-30 Flagship Pioneering Innovations Vii, Llc Compositions and methods for modulation of tumor suppressors and oncogenes
WO2023230566A2 (en) 2022-05-25 2023-11-30 Flagship Pioneering Innovations Vii, Llc Compositions and methods for modulating cytokines
WO2023230578A2 (en) 2022-05-25 2023-11-30 Flagship Pioneering Innovations Vii, Llc Compositions and methods for modulating circulating factors
WO2023250112A1 (en) 2022-06-22 2023-12-28 Flagship Pioneering Innovations Vi, Llc Compositions of modified trems and uses thereof
WO2024077191A1 (en) 2022-10-05 2024-04-11 Flagship Pioneering Innovations V, Inc. Nucleic acid molecules encoding trif and additionalpolypeptides and their use in treating cancer

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994026290A1 (en) * 1993-05-07 1994-11-24 Immunex Corporation Cytokine designated 4-1bb ligand and human receptor that binds thereto
US6673901B2 (en) 1997-06-12 2004-01-06 Research Corporation Technologies, Inc. Artificial antibody polypeptides
US20020151004A1 (en) * 2000-07-24 2002-10-17 Roger Craig Delivery vehicles and methods for using the same
WO2002032925A2 (en) 2000-10-16 2002-04-25 Phylos, Inc. Protein scaffolds for antibody mimics and other binding proteins
WO2004087876A2 (en) * 2003-03-25 2004-10-14 Valeocyte Therapies Llc Use of red blood cells to facilitate cell activation
DE10335833A1 (en) * 2003-08-05 2005-03-03 Curevac Gmbh Transfection of blood cells with mRNA for immune stimulation and gene therapy
FR2873925B1 (en) 2004-08-05 2006-10-13 Erytech Pharma Soc Par Actions METHOD AND DEVICE FOR LYSE-RESCALING FOR THE INCORPORATION OF ACTIVE PRINCIPLE, IN PARTICULAR ASPARAGINASE OR INOSITOL HEXAPHOSPHATE, IN ERYTHROCYTES
FR2884717B1 (en) 2005-04-25 2009-07-03 Erytech Pharma Soc Par Actions ERYTHROCYTES CONTAINING ARGININE DEIMINASE
EP3805245A1 (en) 2005-05-17 2021-04-14 University of Connecticut Compositions and methods for immunomodulation in an organism
WO2007030708A2 (en) 2005-09-08 2007-03-15 Adnexus Therapeutics, Inc. Antimicrobial adzymes and uses thereof
US7462485B2 (en) 2005-10-07 2008-12-09 Glaser Lawrence F Modified erythrocytes and uses thereof
FR2919804B1 (en) 2007-08-08 2010-08-27 Erytech Pharma COMPOSITION AND ANTI-TUMOR THERAPEUTIC VACCINE
FR2925339B1 (en) 2007-12-24 2010-03-05 Erytech Pharma DRUG FOR THE TREATMENT OF PANCREATIC CANCER
ES2405258T3 (en) 2008-02-13 2013-05-30 Erytech Pharma Formulation and procedure for the prevention and treatment of skeletal manifestation of Gaucher disease
FR2928270B1 (en) 2008-03-10 2011-01-21 Erytech Pharma FORMULATION METHOD FOR THE PREVENTION OR TREATMENT OF BONE METASTASES AND OTHER BONE DISEASES
US8211656B2 (en) * 2008-08-13 2012-07-03 The Invention Science Fund I, Llc Biological targeting compositions and methods of using the same
FR2938332B1 (en) 2008-11-07 2011-11-25 Erytech Pharma PREDICTIVE TEST FOR NEUTRALIZATION OF ASPARAGINASE ACTIVITY
FR2944106B1 (en) 2009-04-03 2012-09-28 Erytech Pharma METHOD OF DETERMINING INOSITOL HEXAPHOSPHATE (IHP).
PL2493487T3 (en) 2009-10-27 2017-02-28 Erytech Pharma Composition to induce specific immune tolerance
CA2807942C (en) * 2010-08-10 2021-07-27 Ecole Polytechnique Federale De Lausanne Erythrocyte-binding therapeutics
AU2013203832B2 (en) 2012-03-13 2016-09-15 Celularity Inc. Modified erythrocyte precursor cells and uses thereof
AU2013237419B2 (en) 2012-03-21 2016-04-28 Erytech Pharma Medicament for the treatment of acute myeloid leukemia (AML)
CN103224957B (en) 2013-04-16 2017-08-04 福建三一造血技术有限公司 The method of external evoked generation ASPase containing L II red blood cell medicine
FR3005420B1 (en) 2013-05-07 2015-09-18 Erytech Pharma METHOD OF STABILIZING SUSPENSIONS OF ERYTHROCYTES ENCAPSULATING AN ACTIVE INGREDIENT, SUSPENSIONS OBTAINED
US10260038B2 (en) 2013-05-10 2019-04-16 Whitehead Institute For Biomedical Research Protein modification of living cells using sortase
EP3546485A1 (en) 2013-05-10 2019-10-02 Whitehead Institute for Biomedical Research In vitro production of red blood cells with sortaggable proteins
EP2813234A1 (en) 2013-06-11 2014-12-17 Erytech Pharma Composition of erythrocytes encapsulating phenylalanine hydroxylase and therapeutic use thereof
JP6702866B2 (en) 2013-11-18 2020-06-03 ルビウス セラピューティクス， インコーポレイテッド Synthetic membrane-receiver complex
FR3017299B1 (en) 2014-02-12 2018-05-18 Erytech Pharma PHARMACEUTICAL COMPOSITION COMPRISING ERYTHROCYTES ENCAPSULATING A PLP ENZYME AND ITS COFACTOR
PL3125927T3 (en) 2014-04-01 2021-07-19 Rubius Therapeutics, Inc. Methods and compositions for immunomodulation
US20180135012A1 (en) 2015-05-13 2018-05-17 Rubius Therapeutics, Inc. Membrane-receiver complex therapeutics
EP3187190A1 (en) 2015-12-31 2017-07-05 Erytech Pharma Method of treating a mammal, including human, against cancer using methionine and asparagine depletion
ES2907695T3 (en) 2016-01-11 2022-04-26 Rubius Therapeutics Inc Compositions and methods related to multimodal therapeutic cellular systems for cancer indications
KR20190026819A (en) 2016-07-07 2019-03-13 루비우스 테라퓨틱스, 아이엔씨. Compositions and methods related to therapeutic cell systems expressing exogenous RNA
MX2019006423A (en) * 2016-12-02 2019-08-22 Rubius Therapeutics Inc Compositions and methods related to cell systems for penetrating solid tumors.
KR20190117667A (en) 2017-02-17 2019-10-16 루비우스 테라퓨틱스, 아이엔씨. Functionalized red blood cells
WO2019040516A1 (en) 2017-08-22 2019-02-28 Rubius Therapeutics, Inc. Lipid nanoparticle methods and compositions for producing engineered erythroid cells
EP3703751A2 (en) 2017-11-03 2020-09-09 Rubius Therapeutics, Inc. Compositions and methods related to therapeutic cell systems for tumor growth inhibition
WO2019133881A1 (en) 2017-12-29 2019-07-04 Rubius Therapeutics, Inc. Gene editing and targeted transcriptional modulation for enginerering erythroid cells

Also Published As

Publication number Publication date
WO2017123646A1 (en) 2017-07-20
IL259991A (en) 2018-07-31
US10568910B2 (en) 2020-02-25
JP2019501655A (en) 2019-01-24
IL260010A (en) 2018-07-31
US20180085402A1 (en) 2018-03-29
KR20180095713A (en) 2018-08-27
US20230293588A1 (en) 2023-09-21
BR112018013853A2 (en) 2018-12-18
HRP20220147T1 (en) 2022-04-15
EP3402492A1 (en) 2018-11-21
AU2017207736A1 (en) 2018-07-12
US20200016209A1 (en) 2020-01-16
JP7093302B2 (en) 2022-06-29
PT3402491T (en) 2022-03-03
MX2018008515A (en) 2019-05-09
CA3010510A1 (en) 2017-07-20
CN108778298A (en) 2018-11-09
SI3402491T1 (en) 2022-05-31
PL3402491T3 (en) 2022-04-19
SG10202007639SA (en) 2020-09-29
RS62939B1 (en) 2022-03-31
BR112018013728A2 (en) 2018-12-18
MX2018008514A (en) 2019-05-09
US10517897B1 (en) 2019-12-31
HUE057660T2 (en) 2022-06-28
EP3402492B1 (en) 2022-11-16
US10716811B2 (en) 2020-07-21
JP2021078519A (en) 2021-05-27
WO2017123644A1 (en) 2017-07-20
HK1259079A1 (en) 2019-11-22
CA3009063A1 (en) 2017-07-20
SG11201805442XA (en) 2018-07-30
ES2907695T3 (en) 2022-04-26
US20220072048A1 (en) 2022-03-10
EP3402491B1 (en) 2021-12-22
US20180187155A1 (en) 2018-07-05
DK3402491T3 (en) 2022-02-14
EP3402491A1 (en) 2018-11-21
SG10201913837TA (en) 2020-03-30
JP2022171843A (en) 2022-11-11
US20180193385A1 (en) 2018-07-12
EP4019026A1 (en) 2022-06-29
US10456421B2 (en) 2019-10-29
KR20180095098A (en) 2018-08-24
JP2021112216A (en) 2021-08-05
JP2019501654A (en) 2019-01-24
US20200129556A1 (en) 2020-04-30
LT3402491T (en) 2022-02-25
CN108697733A (en) 2018-10-23
AU2017207738A1 (en) 2018-07-12
CN115969987A (en) 2023-04-18
US20190083540A1 (en) 2019-03-21

Similar Documents

Publication Publication Date Title
SG11201805253SA (en) Compositions and methods related to multimodal therapeutic cell systems for cancer indications
SG11201908719QA (en) Biomarkers and car t cell therapies with enhanced efficacy
SG11201803920TA (en) Compounds and compositions useful for treating disorders related to ntrk
SG11201804373VA (en) Compositions and methods for immunooncology
SG11201807176XA (en) TGFß1-BINDING IMMUNOGLOBULINS AND USE THEREOF
SG11201808622SA (en) Chimeric receptors to flt3 and methods of use thereof
SG11201804787UA (en) Human immunodeficiency virus neutralizing antibodies
SG11201807187XA (en) Binding members to pd-l1
SG11201906223TA (en) Benzisothiazole, isothiazolo[3,4-b]pyridine, quinazoline, phthalazine, pyrido[2,3-d]pyridazine and pyrido[2,3-d]pyrimidine derivatives as kras g12c inhibitors for treating lung, pancreatic or colorectal cancer
SG11201900468YA (en) Anti- gprc5d antibodies, bispecific antigen binding molecules that bind gprc5d and cd3, and uses thereof
SG11201805709RA (en) Anti-pro/latent myostatin antibodies and methods of use thereof
SG11201811152YA (en) Uses of extracellular vesicle comprising a fusion protein having fc binding capacity
SG11201810023QA (en) Anti-tim-3 antibodies and methods of use thereof
SG11201809522WA (en) Method of nucleic acid sequence determination
SG11201807286WA (en) Methods and compositions for transducing lymphocytes and regulated expansion thereof
SG11201804134YA (en) Fgfr2 inhibitors alone or in combination with immune stimulating agents in cancer treatment
SG11201809089QA (en) Bispecific binding proteins and uses thereof
SG11201805136TA (en) Group b adenovirus encoding an anti-tcr-complex antibody or fragment
SG11201900200XA (en) Tgfb antibodies, methods, and uses
SG11201804263PA (en) Cancer treatment using 2-deoxy-2-fluoro-l-fucose in combination with a checkpoint inhibitor
SG11201810579YA (en) Pyrimidin-2-ylamino-1h-pyrazols as lrrk2 inhibitors for use in the treatment of neurodegenerative disorders
SG11201811150WA (en) Ev-mediated delivery of binding protein-small molecule conjugates
SG11201807780XA (en) Customizable facility
SG11201804673WA (en) Novel anti-claudin antibodies and methods of use
SG11201809374VA (en) Cd40l-fc fusion polypeptides and methods of use thereof